Cayasan, Rexcel C.
HRN: 11-42-73 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/02/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
02/02/2024
02/05/2024
IV
500mg
Q8h
Post Op
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes